Mesoblast Limited (MESO): Price and Financial Metrics

Mesoblast Limited (MESO): $1.23

0.00 (0.00%)

POWR Rating

Component Grades








MESO Price/Volume Stats

Current price $1.23 52-week high $5.12
Prev. close $1.23 52-week low $1.16
Day low $1.23 Volume 184,000
Day high $1.29 Avg. volume 280,966
50-day MA $2.12 Dividend yield N/A
200-day MA $3.11 Market Cap 200.29M

MESO Stock Price Chart Interactive Chart >


  • Sentiment is the dimension where MESO ranks best; there it ranks ahead of 86.56% of US stocks.
  • The strongest trend for MESO is in Stability, which has been heading down over the past 177 days.
  • MESO's current lowest rank is in the Quality metric (where it is better than 2.79% of US stocks).

MESO Stock Summary

  • The capital turnover (annual revenue relative to shareholder's equity) for MESO is 0.01 -- better than only 10.21% of US stocks.
  • MESO's price/sales ratio is 26.92; that's higher than the P/S ratio of 95.38% of US stocks.
  • As for revenue growth, note that MESO's revenue has grown -26.56% over the past 12 months; that beats the revenue growth of merely 9.88% of US companies in our set.
  • Stocks that are quantitatively similar to MESO, based on their financial statements, market capitalization, and price volatility, are FF, SNCR, CBAT, INM, and BHIL.
  • Visit MESO's SEC page to see the company's official filings. To visit the company's web site, go to

MESO Valuation Summary

  • In comparison to the median Healthcare stock, MESO's price/sales ratio is 1315.79% higher, now standing at 26.9.
  • MESO's EV/EBIT ratio has moved up 1.5 over the prior 96 months.

Below are key valuation metrics over time for MESO.

Stock Date P/S P/B P/E EV/EBIT
MESO 2023-09-22 26.9 0.4 -2.5 -4.0
MESO 2023-09-21 27.5 0.4 -2.5 -4.1
MESO 2023-09-20 28.4 0.4 -2.6 -4.2
MESO 2023-09-19 29.3 0.4 -2.7 -4.3
MESO 2023-09-18 30.8 0.5 -2.8 -4.5
MESO 2023-09-15 30.8 0.5 -2.8 -4.5

MESO Growth Metrics

    Its 5 year price growth rate is now at 62.41%.
  • The 4 year net cashflow from operations growth rate now stands at 38.01%.
  • Its 5 year revenue growth rate is now at 16.35%.
Over the past 30 months, MESO's revenue has gone down $25,299,000.

The table below shows MESO's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 8.123 -60.463 -85.586
2022-06-30 10.214 -65.782 -91.347
2022-03-31 9.983 -72.618 -91.952
2021-12-31 9.887 -82.97 -97.165
2021-12-31 9.887 -82.97 -97.165
2021-09-30 9.745 -98.12 -96.912

MESO's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • MESO has a Quality Grade of F, ranking ahead of 0.82% of graded US stocks.
  • MESO's asset turnover comes in at 0.01 -- ranking 391st of 680 Pharmaceutical Products stocks.
  • RGEN, STAB, and OTLK are the stocks whose asset turnover ratios are most correlated with MESO.

The table below shows MESO's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.010 1 -2.497
2021-03-31 0.009 1 -2.975
2020-12-31 0.024 1 -2.483
2020-09-30 0.023 1 -2.357
2020-06-30 0.047 1 -1.700
2020-06-30 0.047 1 -1.700

Mesoblast Limited (MESO) Company Bio

Mesoblast Ltd. has established a diverse portfolio of product candidates based on its proprietary allogeneic, off-the-shelf mesenchymal lineage cell-based technology, with multiple active Phase 3 clinical programs. Mesoblast's lead product candidates target major diseases with significant unmet medical needs despite existing therapies. These include chronic heart failure, chronic low back pain due to degenerative disc disease, and immune-mediated conditions such as acute graft versus host disease and biologic refractory rheumatoid arthritis. The company is based in Melbourne, Australia.

MESO Latest News Stream

Event/Time News Detail
Loading, please wait...

MESO Latest Social Stream

Loading social stream, please wait...

View Full MESO Social Stream

Latest MESO News From Around the Web

Below are the latest news stories about MESOBLAST LTD that investors may wish to consider to help them evaluate MESO as an investment opportunity.

Health Care Roundup: Market Talk

Find insight on Ikena Oncology, ATS’s acquisition of Avidity Science, and more in the latest Market Talks covering the Health Care sector.

Yahoo | September 22, 2023

Key Outcomes From FDA Type A Meeting and Mesoblast Next Steps to Achieve RYONCIL Approval

NEW YORK, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an update on the path to approval for its lead-product candidate remestemcel-L in the treatment of pediatric and adult steroid-refractory acute graft versus host disease (SR-aGVHD), following a Type A meeting held with the United States Food and Drug Administration (FDA). FDA clarified that the key remaining issue for pedi

Yahoo | September 21, 2023

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

It's time for another dive into the biggest pre-market stock movers as we check out all the shares worth watching on Wednesday!

William White on InvestorPlace | September 13, 2023

Mesoblast Limited (NASDAQ:MESO) Q4 2023 Earnings Call Transcript

Mesoblast Limited (NASDAQ:MESO) Q4 2023 Earnings Call Transcript August 30, 2023 Operator: Hello and welcome to the Mesoblast Financial Results for the Period Ended June 30, 2023. An announcement and presentation have been lodged with the ASX and are also available on the home and investor page[email protected]. At this time, all participants are in a […]

Yahoo | August 31, 2023

Mesoblast Reports Financial Results and Operational Update for Fiscal Year Ended June 30, 2023

NEW YORK, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today reported financial results and an operational update for the period ended June 30, 2023, and provided an overview of upcoming milestones. Mesoblast Chief Executive Silviu Itescu said: “We had anticipated that remestemcel-L would have been approved by the United States Food and Drug Administration (FDA) for the treatment of pediatric

Yahoo | August 30, 2023

Read More 'MESO' Stories Here

MESO Price Returns

1-mo -16.89%
3-mo -68.54%
6-mo -62.61%
1-year -54.95%
3-year -93.67%
5-year -84.93%
YTD -57.73%
2022 -39.38%
2021 -43.46%
2020 15.20%
2019 78.88%
2018 -29.45%

Continue Researching MESO

Here are a few links from around the web to help you further your research on Mesoblast Ltd's stock as an investment opportunity:

Mesoblast Ltd (MESO) Stock Price | Nasdaq
Mesoblast Ltd (MESO) Stock Quote, History and News - Yahoo Finance
Mesoblast Ltd (MESO) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!